Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary's School of Medicine and Dentistry, Bart's and The London, London, UK.
Horm Metab Res. 2010 Dec;42(13):955-60. doi: 10.1055/s-0030-1267206. Epub 2010 Oct 22.
Type 1 diabetes is an autoimmune disease where β-cells are in a constant process of death and renewal. Reg genes play a role in β-cells regeneration. Reg proteins may be target of an autoimmune response in type 1 diabetes with consequent production of autoantibodies and failure of regeneration. The objective of this work was to characterize the role of Reg1α proteins and anti-Reg1α antibodies as biomarkers of β-cell regeneration and damage. Serum levels of Reg1α protein were investigated in 87 type 1 diabetic subjects (31 newly diagnosed and 56 long standing), 63 type 2 diabetic subjects, 39 subjects with systemic lupus erythematosus (SLE), a nonpancreatic autoimmune disorder, and 64 healthy subjects. The presence of anti-Reg1α antibodies and correlation with metabolic, immune, and genetic parameters were analyzed in diabetic subjects. Increased levels of Reg1α protein were observed in newly diagnosed (p=0.002), and long standing (p=0.001) type 1 diabetes patients and type 2 diabetic subjects (p<0.001). Anti-Reg1α antibodies were found in 47% of patients with type 1 diabetes. No correlation was found with metabolic, immune, and genetic parameters. Patients with SLE showed no increase in Reg1α protein. We report here for the first time raised serum Reg1α protein in type 1 and type 2 diabetes and anti-Reg1α antibodies in type 1 diabetes. Reg1α levels appear not to be influenced by genetic or metabolic control. These findings allow considering future studies on Reg1α protein and autoantibody as new tools in the evaluation and monitoring of β-cells regeneration and autoimmunity.
1 型糖尿病是一种自身免疫性疾病,其中β细胞处于持续死亡和更新的过程中。Reg 基因在β细胞再生中发挥作用。Reg 蛋白可能是 1 型糖尿病自身免疫反应的靶点,导致自身抗体的产生和再生失败。本研究旨在探讨 Reg1α 蛋白和抗 Reg1α 抗体作为β细胞再生和损伤的生物标志物的作用。我们检测了 87 例 1 型糖尿病患者(31 例新诊断,56 例长期患病)、63 例 2 型糖尿病患者、39 例系统性红斑狼疮(SLE)患者(一种非胰腺自身免疫性疾病)和 64 例健康对照者的血清 Reg1α 蛋白水平。分析了糖尿病患者抗 Reg1α 抗体的存在及其与代谢、免疫和遗传参数的相关性。结果发现,新诊断(p=0.002)和长期(p=0.001)1 型糖尿病患者以及 2 型糖尿病患者的血清 Reg1α 蛋白水平升高(p<0.001)。在 47%的 1 型糖尿病患者中发现了抗 Reg1α 抗体。但与代谢、免疫和遗传参数均无相关性。SLE 患者的 Reg1α 蛋白水平无升高。我们首次报道 1 型和 2 型糖尿病患者血清 Reg1α 蛋白升高,1 型糖尿病患者抗 Reg1α 抗体阳性。Reg1α 水平似乎不受遗传或代谢控制的影响。这些发现使我们考虑将来将 Reg1α 蛋白和自身抗体作为评估和监测β细胞再生和自身免疫的新工具进行研究。